Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia Congress

Bagsværd, Denmark (ots/PRNewswire) -

This material is intended for global medical media only.

For journalistic assessment and preparation before publication.

Novo Nordisk announced today that data from 28 abstracts will be
shared at the upcoming World Federation of Hemophilia World Congress
(WFH) in Orlando, Florida, from 24-28 July. The WFH Congress is the
largest international meeting for the global bleeding disorders
community, taking place every second year.

The broad spectrum of data demonstrates exciting new advances in
the area of haemophilia and establishes Novo Nordisk's commitment to
driving innovation and research. The comprehensive programme provides
updates on Novo Nordisk's haemophilia pipeline, new clinical data
regarding established treatments and insights into the psychosocial
and functional impact of haemophilia on quality of life.

Following are key highlights that will be presented at the
meeting:

Monday, July 25, 3:50 pm EDT, Poster Presentation

- Recombinant factor XIII is safe and effective for prophylaxis in
young children with congenital FXIII A-subunit deficiency: results
from an international phase 3 trial (MP-M-200)

Tuesday, July 26, 3:30 pm EDT, Poster Presentations

- Efficacy and safety of turoctocog alfa for prophylaxis and
treatment of bleeding episodes in patients with severe haemophilia
A: results from the guardian(TM)2 trial (P-T-97)
- First report of safety and efficacy of a glycoPEGylated FVIII
(N8-GP) in previously treated paediatric patients with severe
haemophilia A - results from the international phase 3
pathfinder(TM)5 trial (P-T-103)
- Psychosocial impact of mild to severe haemophilia B on affected
adults and children: methods and demographics of the bridging
haemophilia B experiences results and opportunities into solutions
(B-HERO-S) study (PO-T-26)

Wednesday, July 27, 3:30 pm EDT, Poster Presentations

- Bleeding characteristics of patients with congenital haemophilia
and inhibitors: data from a postmarketing study of recombinant
activated factor VII (SMART-7) (P-W-79)

"The presentation of 28 abstracts at WFH 2016 is unparalleled and
a clear signal to the haemophilia community that Novo Nordisk is
committed to finding solutions to improve the lives of people living
with haemophilia worldwide," said Mads Krogsgaard Thomsen, executive
vice president and chief science officer of Novo Nordisk. "We look
forward to the opportunity for scientific exchange at this important
meeting."

The abstracts above are a sampling of the data that will be
presented or published by Novo Nordisk. For a complete list of
abstracts please visit: http://www.wfh.org/congress/2016_Abstracts

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90
years of innovation and leadership in diabetes care. This heritage
has given us experience and capabilities that also enable us to help
people defeat other serious chronic conditions: haemophilia, growth
disorders and obesity. Headquartered in Denmark, Novo Nordisk employs
approximately 41,600 people in 75 countries and markets its products
in more than 180 countries. For more information, visit
novonordisk.com (http://novonordisk.com), Facebook
(http://www.facebook.com/novonordisk), Twitter
(http://www.twitter.com/novonordisk), LinkedIn
(http://www.linkedin.com/company/novo-nordisk), YouTube
(http://www.Youtube.com/novonordisk)

Further information
Media:

Katrine Sperling

+45-4442-6718

krsp@novonordisk.com

Åsa Josefsson

+45-3079-7708

aajf@novonordisk.com

Courtney Mallon

+1-609-786-4079

cyml@novonordisk.com

Investors:

Peter Hugreffe Ankersen

+45-3075-9085

phak@novonordisk.com

Melanie Raouzeos

+45-3075-3479

mrz@novonordisk.com

Kasper Veje (US)

+1-609-235-8567

kpvj@novonordisk.com

ots Originaltext: Novo Nordisk A/S
Im Internet recherchierbar: http://www.presseportal.de